MedImmune hosts 10 finalists to present at its Fourth Annual Research Abstract Competition, highlighting the work of tomorrow's potential scientific leaders in respiratory disease, inflammation, and autoimmunity. Postdoctoral student of Harvard Medical School and Brigham & Women’s Hospital, Eric Boilard, wins first place for his research on the role of platelets in amplifying inflammation in arthritis.
MedImmune announces winners of first European Cancer Research Abstract Competition which highlights the work of tomorrow’s scientific leaders in cancer research. First prize of £2,000 was awarded to Nicole Simonavicius, a PhD student at The Institute of Cancer Research, London, UK for her research into the role of the tumour pericyte receptor endosialin in angiogenesis.
MedImmune presents data on several inflammatory disease programs at the 73rd annual meeting of the American College of Rheumatology in Philadelphia, Pennsylvania.
MedImmune presents four abstracts on respiratory syncytial virus (RSV) and influenza at the 2009 American Academy of Pediatrics National Conference & Exhibition.
Interim clinical trial results show MedImmune’s H1N1 nasal spray vaccine demonstrates a similar clinical profile to the seasonal vaccine in eligible children and adults, 2 to 49 years of age.
MedImmune presents four abstracts at the 47 th Annual Meeting of the Infectious Disease Society of America which advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention.
MedImmune receives an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus from the U.S. Department of Health and Human Services.
The Gazette of Politics and Business recognizes MedImmune as the top business in the State of Maryland. This esteemed award is based on annual revenue, employee growth, product or service innovations, community service efforts, and steerage through the economic downturn.
MedImmune advances three oncology antibody programs into Phase 1 clinical development within the past six months. All three antibody candidates target a variety of advanced solid tumors, but via different pathways.
MedImmune launches “Don’t Play with the Flu,”™ a national health awareness campaign in partnership with Women’s Professional Soccer and the American Youth Soccer Organization. Mia Hamm and Brandi Chastain, soccer champions and moms, kick off the campaign which highlights the importance of getting a seasonal influenza vaccination every year.
MedImmune begins shipping FluMist® (Influenza Virus Vaccine Live, Intranasal) for the 2009-2010 influenza season.
MedImmune was awarded a contract to manufacture monovalent (single-strain) live attenuated influenza vaccine for Novel Influenza A (H1N1) to vaccinate priority populations by the U.S. Department of Health and Human Services (HHS). An initial $90 million of vaccine has been placed.
MedImmune expands assistance program for Synagis® (palivizumab) to qualify as many as 75 percent of U.S. households to receive the antibody at no cost.
MedImmune funds the first observational prospective study to assess the full burden of respiratory syncytial virus (RSV) among preterm infants.
For the sixth consecutive year, MedImmune awards five fellowship research grants to advance viral respiratory disease research. The grant candidates, which are required to be full-time fellows conducting original research as their primary focus in an American Board of Pediatrics-accredited fellowship program receive $35,000 each.
MedImmune presents data at the 2009 Pediatric Academic Societies' (PAS) annual meeting in Baltimore, MD which suggests that Flumist (Influenza Vaccine Live, Intranasal) has an acceptable safely profile among mild to moderately immunocompromised children with cancer.
MedImmune sponsors a recent study, which is continuous evidence that, late-preterm infants face greater morbidity and healthcare costs up to at least one year after birth. The analysis suggests that even mild prematurity is associated with increased risk of medically attended RSV infection, and that this risk is higher among infants exposed to supplemental oxygen or assisted ventilation during the neonatal period.
500 MedImmune employees from Engineering, Public Affairs and Sales Training partner with St. Jude for a community service project. Employee teams painted, landscaped and assembled care kits at the ranch.
During the Annual Meeting for the American Association of Cancer Research, MedImmune showcases its commitment to cancer research with the presentation of eleven abstracts on the progress that has been made in various oncology programs.
MedImmune submits a Marketing Authorization Application in the European Union for the Intranasal Vaccine to Prevent Seasonal Influenza. The MAA submission for LAIV is based on data from 73 global clinical and U.S. post-marketing studies of more than 141,000 subjects that are conducted in 38 countries.
**
FluMist® Prescribing Information